PIII PREVENT RCT (n=555) found 52 weeks of treatment with secukinumab 150mg every 4 weeks was superior to placebo for 40% improvement in disease activity according to Assessment of Spondyloarthritis International Society criteria (39.8% vs 19.9% p<0.05). No new safety findings were reported .
Positive new data from the ongoing PIII PREVENT trial. This 2 yr trial is evaluating the efficacy and safety of secukinumab in nr-axSpA. The trial has met its primary endpoint of ASAS40 (=improvement of at least 40% and of at least 10 units on a 0-100 scale in >3 of the following: patient global assessment, pain assessment, function, and inflammation.
PIII (NCT02696031) study to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with non-radiographic axial spondyloarthritis at Week 16 as well as week 52 and long term efficacy and safety up to Week 104 starts. 555 adults will be recruited from the US, Austria, France, Germany & the UK. Primary outcome is the proportion of participants who achieved an ASAS 40 response (Assessment of SpondyloArthritis International Society criteria); collection of these data should complete Nov 19 .